Nurix Therapeutics Inc
NASDAQ:NRIX

  • LAST PRICE
    16.0500
  • TODAY'S CHANGE (%)
    0.3000 (1.9048%)
  • Bid / Lots
    14.7700/ 2
  • Ask / Lots
    17.0100/ 13
  • Open / Previous Close
    16.2000 / 15.7500
  • Day Range
    15.7600
    17.1000
  • 52 Week Range
    4.2200
    18.1200
  • Volume
    599,519

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
NRIX
Nurix Therapeutics Inc
934.0M
-6.1x
---
CVAC
CureVac NV
872.5M
-3.3x
---
ARQT
Arcutis Biotherapeutics Inc
967.8M
-2.8x
---
GYRE
Gyre Therapeutics Inc
971.4M
-5.7x
---
PRTA
Prothena Corporation PLC
1.1B
-6.8x
---
RGNX
Regenxbio Inc
706.8M
-2.5x
---
As of 2024-06-03

Company Information

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Contact Information

Headquarters
1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006
Phone
415-660-5320
Fax
415-525-4200

Executives

Independent Chairman of the Board
Julia Gregory
President, Chief Executive Officer, Director
Arthur Sands
Chief Financial Officer
Hans van Houte
Chief Technical Officer
Pasit Phiasivongsa
Chief Scientific Officer
Gwenn Hansen

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$934.0M
Revenue (TTM)
$80.9M
Shares Outstanding
59.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.17
EPS
$-2.65
Book Value
$4.12
P/E Ratio
-6.1x
Price/Sales (TTM)
11.5
Price/Cash Flow (TTM)
---
Operating Margin
-194.51%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.